{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:19:41Z","timestamp":1768011581779,"version":"3.49.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[1998,10]]},"abstract":"<jats:p><jats:italic>Abstract<\/jats:italic>\u2014Activation of the renin-angiotensin system may contribute to the derangement in renal and cardiac function in congestive heart failure. The present study evaluated the effects of eprosartan, a selective angiotensin II receptor antagonist, on renal hemodynamic and excretory parameters and on the development of cardiac hypertrophy in rats with aortocaval fistula, an experimental model of congestive heart failure. Infusion of eprosartan (1.0 mg\/kg) in rats with aortocaval fistula produced a significant increase (+34%) in total renal blood flow and a sustained decrease (\u221233%) in the calculated renal vascular resistance. These effects on renal hemodynamics were more pronounced than those observed in sham-operated control rats and occurred despite a significant fall (\u221212%) in mean arterial blood pressure. Moreover, eprosartan caused a preferential increase in renal cortical blood perfusion and significantly increased glomerular filtration in rats with congestive heart failure. Chronic administration of eprosartan (5.0 mg\/kg per day for 7 days through osmotic minipumps inserted intraperitoneally on the day of operation) resulted in a significant enhancement of urinary sodium excretion compared with nontreated rats with heart failure. Moreover, administration of eprosartan to salt-retaining rats with congestive heart failure resulted in a progressive increase and ultimate recovery in urinary sodium excretion. Finally, early treatment with eprosartan blocked the development of cardiac hypertrophy in rats with aortocaval fistula to a larger extent than the angiotensin-converting enzyme inhibitor enalapril. These findings emphasize the importance of angiotensin II in mediating the impairment in renal function and induction of cardiac hypertrophy in heart failure and further suggest that angiotensin II receptor blockade may be a useful treatment of these consequences in severe cardiac failure.<\/jats:p>","DOI":"10.1161\/01.hyp.32.4.746","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:53:46Z","timestamp":1339462426000},"page":"746-752","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":37,"title":["Effects of Eprosartan on Renal Function and Cardiac Hypertrophy in Rats With Experimental Heart Failure"],"prefix":"10.1161","volume":"32","author":[{"given":"Sergey","family":"Brodsky","sequence":"first","affiliation":[{"name":"From the Department of Physiology and Biophysics, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel (S.B., K.G., Z.A., A.H., J.W.), and Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (R.R.R., G.Z.F.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Gurbanov","sequence":"additional","affiliation":[{"name":"From the Department of Physiology and Biophysics, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel (S.B., K.G., Z.A., A.H., J.W.), and Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (R.R.R., G.Z.F.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaid","family":"Abassi","sequence":"additional","affiliation":[{"name":"From the Department of Physiology and Biophysics, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel (S.B., K.G., Z.A., A.H., J.W.), and Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (R.R.R., G.Z.F.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Hoffman","sequence":"additional","affiliation":[{"name":"From the Department of Physiology and Biophysics, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel (S.B., K.G., Z.A., A.H., J.W.), and Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (R.R.R., G.Z.F.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Robert R.","family":"Ruffolo","sequence":"additional","affiliation":[{"name":"From the Department of Physiology and Biophysics, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel (S.B., K.G., Z.A., A.H., J.W.), and Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (R.R.R., G.Z.F.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giora Z.","family":"Feuerstein","sequence":"additional","affiliation":[{"name":"From the Department of Physiology and Biophysics, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel (S.B., K.G., Z.A., A.H., J.W.), and Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (R.R.R., G.Z.F.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Winaver","sequence":"additional","affiliation":[{"name":"From the Department of Physiology and Biophysics, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel (S.B., K.G., Z.A., A.H., J.W.), and Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (R.R.R., G.Z.F.)."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1987.156"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108431"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.63.3.7006851"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(87)80014-8"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-2828(90)90086-H"},{"key":"e_1_3_2_6_2","first-page":"R776","volume":"254","year":"1988","unstructured":"Winaver J, Hoffman A, Burnett JC Jr, Haramati A. Hormonal determinants of sodium excretion in rats with experimental high-output heart failure. Am J Physiol. 1988;254:R776\u2013R784.","journal-title":"Am J Physiol"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/res.55.5.6091942"},{"key":"e_1_3_2_8_2","first-page":"S","volume":"38","year":"1990","unstructured":"Ichikawa I, Yoshioka T, Fogo A, Kon V. Role of angiotensin II in altered glomerular hemodynamics in congestive heart failure. Kidney Int. 1990;38:S-123\u2013S-126.","journal-title":"Kidney Int"},{"key":"e_1_3_2_9_2","unstructured":"Hall JE Brands MW. The renin-angiotensin-aldosterone systems: renal mechanisms and circulatory homeostasis. In: Seldin DW Giebisch G eds. The Kidney: Physiology and Pathophysiology. New York NY: Raven Press; 1992:1455\u20131504."},{"key":"e_1_3_2_10_2","unstructured":"Pfeffer JM Pfeffer MA Braunwald E. Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure. Circulation. 1987;75(suppl I):I-149\u2013I-155."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209033271001"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209033271003"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119360"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/res.72.6.7684331"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199606203342507"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430130027004"},{"key":"e_1_3_2_18_2","first-page":"139","volume":"15","year":"1994","unstructured":"Sweet CS, Rucinska EJ. Losartan in heart failure: preclinical experiences and initial clinical outcomes. Eur Heart J. 1994;15:139\u2013144.","journal-title":"Eur Heart J"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(96)90067-8"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.88.4.8403307"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.91.3.691"},{"key":"e_1_3_2_22_2","first-page":"H250","volume":"263","year":"1992","unstructured":"Fitzpatrick MA, Rademaker MT, Charles CJ, Yandle TG, Espiner EA, Ikram H. Angiotensin II receptor antagonism in ovine heart failure: acute hemodynamic, hormonal, and renal effects. Am J Physiol. 1992;263:H250\u2013H256.","journal-title":"Am J Physiol"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0022-3565(25)38470-3","volume":"268","year":"1994","unstructured":"Abassi ZA, Kelly G, Golomb E, Klein H, Keiser HR. Losartan improves the natriuretic response to ANF in rats with high-output heart failure. J Pharmacol Exp Ther. 1994;268:224\u2013268.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_24_2","unstructured":"Spinale FG de Gasparo M Whitebread S Hebbar L Clair MJ Melton M Krombach SR Mukherjee R Iannini JP O SJ. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure I: effects on left ventricular performance and neurohormonal systems."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.30.2.240"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00164582"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1988.49"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.96.10.3655"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.92.9.2385"},{"key":"e_1_3_2_30_2","first-page":"921","volume":"87","year":"1992","unstructured":"Ruzicka M, Yuan B, Harmsen E, Leenen FHH. The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats. Circulation. 1992;87:921\u2013930.","journal-title":"Circulation"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1973.122"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1990.259.1.C84"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.1996.271.6.F1166"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01473295"},{"key":"e_1_3_2_35_2","first-page":"515","volume":"118","year":"1991","unstructured":"Villarreal D, Freeman RH. ANF and the renin-angiotensin system in the regulation of sodium balance: longitudinal studies in experimental heart failure. J Lab Clin Med. 1991;118:515\u2013522.","journal-title":"J Lab Clin Med"},{"key":"e_1_3_2_36_2","first-page":"H2139","volume":"272","year":"1997","unstructured":"Maeda Y, Wada A, Tsutamoto T, Fukai D, Kinoshita M. Chronic effects of ANG II antagonist in heart failure: improvement of cGMP generation from ANP. Am J Physiol. 1997;272:H2139\u2013H2145.","journal-title":"Am J Physiol"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1993.00410080011002"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.96.11.4065"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.92.10.3105"},{"key":"e_1_3_2_40_2","first-page":"772","volume":"20","year":"1992","unstructured":"Smits JFM. Angiotensin II receptor blockade after myocardial infarct in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol. 1992;20:772\u2013778.","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.HYP.32.4.746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T21:51:48Z","timestamp":1743371508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.HYP.32.4.746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,10]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1998,10]]}},"alternative-id":["10.1161\/01.HYP.32.4.746"],"URL":"https:\/\/doi.org\/10.1161\/01.hyp.32.4.746","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,10]]},"assertion":[{"value":"1998-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-05-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}